Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors

Ibarra, R; Rojas, Daniel; Snyder, Laura; Yao, Min; Fabien, Jeffrey; Milano, Michael T.; Katz, Alan W.; Goodman, Karyn A.; Stephans, Kevin L.; El-Gazzaz, Galal; Aucejo, Federico; Miller, Charles; Fung, John J.; Lo, Simon S.; Machtay, Mitchell; Sanabria, Juan

doi:10.3109/0284186x.2011.652736

Cited by 94 publications

(68 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, if we examine only the IHCC cases, the results of large Surveillance Epidemiology and End Result (SEER) database supports the use of radiation against no treatment (median survival 7 vs. 3 months; p<0.01) [27]. Several other studies have supported the use of radiotherapy in IHCC with median survival ranging from 7-15.3 months with conventional fractionated doses of radiation (45-50 Gy) [28][29][30][31][32]. Furthermore, combination of transarterial chemotherapy with radiation is associated with improved survival (13.3 vs. 7.8 months) [29,30].…”

Section: Intrahepatic Cholangiocarcinomamentioning

confidence: 99%

Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence

Chopra

Mathew

Shrivastava

2014

Indian J Gastroenterol

View full text Add to dashboard Cite

Cholangiocarcinoma is a rare malignancy of the bile ducts. The current standard of care for unresectable nonmetastatic disease is doublet systemic chemotherapy, which provides a median survival of 11.7 months. Although chemoradiation is a therapeutic option that provides almost equivalent or superior survival, the lack of level I evidence presents a major hurdle in routinely recommending it within multidisciplinary clinics. This mini review presents the current evidence on the use of chemoradiation for unresectable nonmetastatic cholangiocarcinoma and rationale for positioning it within multidisciplinary management of unresectable cholangiocarcinomas.

show abstract

Section: Intrahepatic Cholangiocarcinomamentioning

confidence: 99%

Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence

Chopra

Mathew

Shrivastava

2014

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Application of SBRT technique in the treatment of HCC with PVTT can make the HCC and PVTT accurately localize high-dose radiation and avoid the surrounding normal liver tissue damage, so as to gain a better therapeutic effect. In the USA, a multicenter clinical trial showed that for the non-resectable HCC patients treated with SBRT, the overall freedom from local progression was 63% at a median follow-up of 12.9 months, the median time to local progression was 6.3 months, the 1-and 2-years overall survival rates were 87% and 55%, respectively [43]. The local and regional recurrence remain the major causes of SBRT failure; further studies of combination of SBRT and other treatment modalities need to be carried out.…”

Section: Radiotherapy (Rt)mentioning

confidence: 99%

The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus

Zhang

Lai

Zhang

et al. 2015

International Journal of Surgery

144

View full text Add to dashboard Cite

For those resectable tumors, the better choice for treatment of HCC with PVTT should be hepatectomy and removal of PVTT. For those unresectable tumors, TACE (especially the super-selective TACE) has been the preferred palliative treatment, the other regional interventional therapy and/or radiotherapy could improve the therapeutic effects. The multidisciplinary treatments may further improve the quality of life and prolong the survival period for the HCC patients associated with PVTT.

show abstract

“…Certain works limit themselves to the RECIST criteria. [18][19][20][21][22] Other publications apply recommended EASL or mRECIST criteria. [23][24][25][26][27] A single article compared the RECIST and EASL criteria in this indication.…”

Section: Evaluation Of Response After Sbrt For Primary Hepatic Tumorsmentioning

confidence: 99%

Evaluation of response after SBRT for liver tumors

Tétreau

Llacer

Riou

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for hepatic metastases. Response of liver metastases to SBRT is better assessed with a combination of size and enhancement pattern. The occurrence of a lobulated enhancement during follow up is efficient to predict local progression in a specific, reproducible, and sensitive way. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and functional criteria than routine imaging and metric evaluation alone.

show abstract

Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors

Abstract: (2012) Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors, Acta Oncologica, 51:5, 575-583,

Cited by 94 publications

References 34 publications

Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence

Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence

The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus

Evaluation of response after SBRT for liver tumors

Contact Info

Product

Resources

About